Drug Trial Radar · NCT06653153
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,400
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
Apr 2029
Study completion Oct 2030
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Conditions
- Alzheimer's Disease
Interventions
RemternetugDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)Time frame: Baseline to Time to Event up to Week 255
Locations
262 sites in 10 countries. Site status is shown where the registry gives one.
Parkway Medical Center
Birmingham, Alabama
MD First Research - Chandler
Chandler, Arizona
Care Access - 801 South Power Road, Mesa
Mesa, Arizona
Banner Alzheimer's Institute
Phoenix, Arizona
Banner Alzheimer's Institute Tucson
Tucson, Arizona
Neuro-Pain Medical Center
Fresno, California
Care Access - Huntington Beach
Huntington Beach, California
Inglewood Clinical
Inglewood, California
Irvine Clinical Research
Irvine, California
Healthy Brain Clinic
Long Beach, California
Riverside Clinical
Riverside, California
Clinical Trials Research
Sacramento, California
Artemis Institute for Clinical Research
San Diego, California
Sharp Neurocognitive Research Center
San Diego, California
Ray Dolby Brain Health Center
San Francisco, California
The Neuron Clinic - San Marcos
San Marcos, California
Syrentis Clinical Research
Santa Ana, California
Providence Medical Foundation
Santa Rosa, California
California Neuroscience Research, LLC
Sherman Oaks, California
Care Access - Aurora
Aurora, Colorado
Mountain Neurological Research Center
Basalt, Colorado
Alpine Clinical Research Center
Boulder, Colorado
CenExel Rocky Mountain Clinical Research
Englewood, Colorado
Invicro
New Haven, Connecticut
Ki Health Partners, LLc, dba New England Institute for Clinical Research
Stamford, Connecticut
JEM Research Institute
Atlantis, Florida
VIN - Aventura
Aventura, Florida
Bradenton Research Center, Inc.
Bradenton, Florida
K2 Medical Research WINTER GARDEN
Clermont, Florida
TecTum Research
Davie, Florida
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Indago Research & Health Center, Inc
Hialeah, Florida
K2 MEDICAL Research THE VILLAGES
Lady Lake, Florida
ClinCloud
Maitland, Florida
K2 Medical Research ORLANDO
Maitland, Florida
ClinCloud
Melbourne, Florida
Merritt Island Medical Research, LLC
Merritt Island, Florida
VIN-Andrew Lerman
Miami, Florida
New Age Medical Research Corporation
Miami, Florida
Showing 40 of 262 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.